Mustang Bio is an American clinical-stage biopharmaceutical company founded in 2015 and headquartered in Worcester, MA, U.S. Operating as a partner company of Fortress Biotech, Mustang Bio develops CAR-T immunotherapies and gene therapies for multiple diseases, including hematologic cancers, solid tumors, and X-linked severe combined immunodeficiency (X-SCID).
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| MBIO | MUSTANG BIO, INC. | 2025-10-30 18:58:45 | 1.42 | -0.04 | -2.74 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MBIO | 0001680048 | MUSTANG BIO, INC. | US62818Q3020 | 5493004W0VC1DPECQ779 | 473828760 | Nasdaq | 2834 | Pharmaceutical Preparations | 1231 | DE | 95 SAWYER RD | WALTHAM | MA | 02453 | UNITED STATES | US | 7816524500 | 95 SAWYER RD, WALTHAM, MA, 02453 | 95 SAWYER RD, WALTHAM, MA, 02453 | — | Biopharmaceuticals | 2015 | Manuel Litchman | — | http://mustangbio.com | 14,800,000 | 7,320,444 | 24,976,289 | Mustang Bio is an American clinical-stage biopharmaceutical company founded in 2015 and headquartered in Worcester, MA, U.S. Operating as a partner company of Fortress Biotech, Mustang Bio develops CAR-T immunotherapies and gene therapies for multiple diseases, including hematologic cancers, solid tumors, and X-linked severe combined immunodeficiency (X-SCID). | 2025-10-30 17:36:52 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2024 | 14,800,000 | -23,900,000 | -61.7571 | — | — | — |
| 2023 | 38,700,000 | -10,100,000 | -20.6967 | — | — | — |
| 2022 | 48,800,000 | 48,800,000 | 100 | — | — | — |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Manuel Litchman | Chief Executive Officer, President | 2021 | 450,000 | 225,000 | 209,230 | 0 | 852 | 885,082 |
| Brian Achenbach | Corporate Controller, Senior Vice President | 2021 | 278,543 | 97,490 | 47,925 | 0 | 0 | 423,958 |
| Brian Achenbach | Corporate Controller, Senior Vice President | 2020 | 269,000 | 77,350 | 164,700 | 0 | 0 | 511,050 |
| Manuel Litchman | Chief Executive Officer, President | 2020 | 430,000 | 176,044 | 560,285 | 0 | 827 | 1,167,156 |
| Brian Achenbach | Corporate Controller, Senior Vice President | 2019 | 256,862 | 45,500 | 98,350 | 0 | 0 | 400,712 |
| Fiscal Year | Employee Count |
|---|---|
| 2024 | 6 |
| 2023 | 80 |
| 2019 | 51 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | — | — | — |
| Cost Of Revenue | — | — | — |
| Gross Profit | — | — | — |
| Research And Development Expenses | 7,557,000 | 40,513,000 | 62,475,000 |
| General And Administrative Expenses | 4,135,000 | 9,686,000 | 12,210,000 |
| Operating Expenses | 16,245,000 | 49,260,000 | 76,159,000 |
| Operating Income | -16,245,000 | -49,260,000 | -76,159,000 |
| Net Income | -15,752,000 | -51,602,000 | -77,525,000 |
| Earnings Per Share Basic | -38.57 | -6 | -0.75 |
| Earnings Per Share Diluted | -38.57 | -6 | -0.75 |
| Weighted Average Shares Outstanding Basic | 609,696 | 8,604,104 | 103,432,603 |
| Weighted Average Shares Outstanding Diluted | 609,696 | 8,604,104 | 103,432,603 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash And Cash Equivalents | 6,839,000 | 6,234,000 | 75,656,000 |
| Marketable Securities Current | — | — | — |
| Accounts Receivable | — | — | — |
| Inventories | — | — | — |
| Non Trade Receivables | 402,000 | 0 | 36,000 |
| Other Assets Current | — | — | — |
| Total Assets Current | 8,606,000 | 11,346,000 | 78,852,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 371,000 | 3,218,000 | 9,391,000 |
| Other Assets Non Current | 250,000 | 833,000 | 261,000 |
| Total Assets Non Current | 702,000 | 6,396,000 | 13,570,000 |
| Total Assets | 9,308,000 | 17,742,000 | 92,422,000 |
| Accounts Payable | 7,464,000 | 6,322,000 | 6,833,000 |
| Deferred Revenue | — | — | — |
| Short Term Debt | — | — | — |
| Other Liabilities Current | 2,667,000 | 834,000 | — |
| Total Liabilities Current | 12,609,000 | 15,371,000 | 15,109,000 |
| Long Term Debt | — | — | — |
| Other Liabilities Non Current | — | — | — |
| Total Liabilities Non Current | 572,000 | 2,248,000 | 31,040,000 |
| Total Liabilities | 13,181,000 | 17,619,000 | 46,149,000 |
| Common Stock | 0 | 0 | 0 |
| Retained Earnings | -396,723,000 | -380,971,000 | -329,369,000 |
| Accumulated Other Comprehensive Income | — | — | — |
| Total Shareholders Equity | -3,873,000 | 123,000 | 46,273,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Depreciation And Amortization | 671,000 | 1,860,000 | 2,723,000 |
| Share Based Compensation Expense | -450,000 | 568,000 | 2,283,000 |
| Other Non Cash Income Expense | 0 | 1,466,000 | -255,000 |
| Change In Accounts Receivable | — | — | — |
| Change In Inventories | — | — | — |
| Change In Non Trade Receivables | -494,000 | 3,616,000 | -14,000 |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | — | — | — |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | -11,410,000 | -49,477,000 | -65,066,000 |
| Purchases Of Marketable Securities | — | — | — |
| Sales Of Marketable Securities | — | — | — |
| Acquisition Of Property Plant And Equipment | 0 | 64,000 | 2,714,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | 0 | 5,886,000 | -2,952,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 6,512,000 | 178,000 | 206,000 |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | 11,265,000 | -26,081,000 | 34,056,000 |
| Change In Cash | -145,000 | -69,672,000 | -33,962,000 |
| Cash At End Of Period | 6,839,000 | 6,234,000 | 75,656,000 |
| Income Taxes Paid | — | — | — |
| Interest Paid | 0 | 1,352,000 | 2,710,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Earnings Per Share | -38.57 | -6 | -0.75 |
| Price To Earnings Ratio | -0.2295 | -11.25 | -394.8803 |
| Earnings Growth Rate | 542.8333 | 700 | — |
| Price Earnings To Growth Ratio | -0.0004 | -0.0161 | — |
| Book Value Per Share | -6.3523 | 0.0143 | 0.4474 |
| Price To Book Ratio | -1.3932 | 4,721.7644 | 661.9977 |
| Ebitda | -15,076,000 | -45,633,000 | -71,443,000 |
| Enterprise Value | — | — | — |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | — | — | — |
| Capital Expenditures | -2,176,000 | -4,313,000 | 1,062,000 |
| Free Cash Flow | -9,234,000 | -45,164,000 | -66,128,000 |
| Return On Equity | 4.0671 | -419.5285 | -1.6754 |
| One Year Beta | 3.7114 | 1.4108 | 1.699 |
| Three Year Beta | 1.9941 | 1.5928 | 1.5303 |
| Five Year Beta | 1.6748 | 1.5276 | 1.4224 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Fortress Biotech, Inc. | 10% owner | 2025-09-29 | 59,334 | A | 258,192 |
| Litchman Manuel MD | Director, President, CEO and Interim CFO | 2025-04-24 | 27 | D | 1,634 |
| Fortress Biotech, Inc. | 10% owner | 2025-03-31 | 67,806 | A | 198,858 |
| Fortress Biotech, Inc. | 10% owner | 2024-06-27 | 575,191 | A | 2,502,991 |
| Litchman Manuel MD | Director, President and CEO | 2024-05-31 | 1,396 | D | 83,024 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| MORGAN STANLEY | 2025-06-30 | 226 | 237 | 0.9536 |
| Tower Research Capital LLC (TRC) | 2025-06-30 | 3,799 | 3,978 | 0.955 |
| RAYMOND JAMES FINANCIAL INC | 2025-06-30 | 16 | 16 | 1 |
| CITADEL ADVISORS LLC | 2025-06-30 | 26,809 | 28,069 | 0.9551 |
| BANK OF AMERICA CORP /DE/ | 2025-06-30 | 32 | 33 | 0.9697 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| FIDELITY CONCORD STREET TRUST | 2025-08-31 | Fidelity Series Total Market Index Fund | FCFMX | 2,876 | 4,342.76 | 0.0 |
| FIDELITY CONCORD STREET TRUST | 2025-08-31 | Fidelity Total Market Index Fund | FSKAX | 1,077 | 1,626.27 | 0.0 |
| FIDELITY CONCORD STREET TRUST | 2025-08-31 | Fidelity Extended Market Index Fund | FSMAX | 18,944 | 28,605.44 | 0.0001 |
| VANGUARD INDEX FUNDS | 2025-06-30 | Institutional Select Shares | VSEMX | 1,468 | 1,402.09 | 0.0 |
| VANGUARD INDEX FUNDS | 2025-06-30 | Institutional Plus Shares | VEMPX | 1,468 | 1,402.09 | 0.0 |